Real-world Management Outcomes in Patients With Hepatocellular Carcinoma

Real-World Management Outcomes in Patients With Hepatocellular Carcinoma Objective of study To evaluate real-world clinical outcomes and management strategies in patients diagnosed with unresectable hepatocellular carcinoma. The study aims to provide insights into treatment patterns and their effectiveness in routine clinical practice. This is a multicounty, multicenter, non-interventional, retrospective study Download Full Report What is HCC? (Hepatocellular Carcinoma) Hepatocellular carcinoma (HCC), the most common type of liver cancer, originates from hepatocytes the primary functional cells of the liver. It is closely associated with underlying liver diseases such as cirrhosis and chronic hepatitis infections. Early detection of HCC is crucial, as the disease often progresses silently and can metastasize rapidly, reducing treatment options and survival rates. Globally, the prevalence of HCC varies, with approximately 800,000 new cases diagnosed each year. Despite its severity, awareness about HCC remains low, underscoring the urgent need for widespread screening and timely intervention to improve outcomes Download the Case Study Background of HCC Causes The exact cause of this condition is not clear, but theproposed causes include: Chronic infection with certainhepatitis viruses, DNA mutation of the liver cells Risk factors Cirrhosis, Older age, Certain inherited liver disease, Genetic predisposition, Diabetes, Obesity , Exposure to certain chemicals, Excessive alcohol consumption, Gender-Male Symptoms Abdominal pain, jaundice, dark urine, reduced appetite, unintended weight loss, nausea & vomiting, abdominal swelling Diagnosis Blood tests(LFT,CBC , etc.) , Imaging tests(USG,CT Scan,MRI), Biopsy Treatment Surgery, Ablation, Embolization therapy Overview of Study Download Full Report Data Source Medical Records Electronic Health Records Database Healthcare Centers Data Source Medical Records Electronic Health Records Database Healthcare Centers Data Collection Demographic Clinical Treatment Survival Data Collection Demographic Clinical Treatment Survival Patient’s characteristics Disease stage Treatment modalities Response rates Survival outcomes Patient’s characteristics Disease stage Treatment modalities Response rates Survival outcomes Analysis Statistical Analysis Descriptive Analysis Analysis Statistical Analysis Descriptive Analysis Countries Involved Europe, Taiwan India, Egypt Hong Kong, Russia Saudi Arabia, Singapore UAE, Brazil Oman, Kuwait Countries Involved Europe, Taiwan India, Egypt Hong Kong, Russia Saudi Arabia, Singapore UAE, Brazil Oman, Kuwait Insights of reports Study data was summarized and analyzed to get insight into the data. Summary of Patients Statement of Death The report aims to determine whether patients experienced death related to HCC or its treatment. Death related to HCC or its treatment:218 patients (approximately 21.0% of the study population) experienced death that was either directly related to HCC itself or its treatment. Death not related to HCC or its treatment: 13 patients (approximately 1.3% of the study population) did not experience death related to HCC or its treatment. Summary of Patients Status at last contact The report assessed the patient’s status at the date of data extraction to determine the current outcome of the study population. Patients Alive: There were 113 patients (approximately 10.9% of the study population) who were still alive. Patients Deceased: There were 223 patients (approximately 21.5% of the study population) who had passed away Summary of Patients Treatment History for Loco-Regional Therapy The report analyzed whether patients had a history of loco-regional therapy for HCC, such as liver transplantation, surgical resection, ablation, or other treatments, both before and after the index date Summary of Patients Loco-Regional Therapy The study aims to analyze the use of Trans Arterial Chemo-Embolization (TACE) in the management of HCC. Specifically, it will determine the proportion of patients who underwent conventional TACE and those who received drug-eluting bead TACE before and after the index date Retrospective Nature Limited Treatment Details Selection Bias Generalizability Survivorship Bias Data Quality and Completeness Experienced in delivering more than 200+ studies across multiple therapeutic areas Download Full Report Summary By conducting a multicounty, multicenter, non-interventional, and retrospective analysis, the study aimed to describe the diverse treatment approaches and their impact on patient outcomes. In this study analysis was done on basis of following four factors – Summary of Patients Statement of Death Summary of Patients Status at Last Contact Summary of Patients Treatment History for Loco-Regional Therapy Summary of Patients Loco-Regional Therapy Conclusion The real-world evidence gathered through this multi-country, multi-center, retrospective study offers valuable insights into the clinical management and outcomes of patients with unresectable hepatocellular carcinoma (HCC). By analyzing patient mortality, survival status, and loco-regional therapy usage, the study underscores the complexity and variation in current treatment strategies. This evidence contributes to a deeper understanding of how therapies such as TACE (Trans Arterial Chemo-Embolization) are utilized in practice and highlights their role in shaping patient outcomes. The findings support more informed clinical decision-making, encourage the adoption of patient-centric care models, and offerguidance for policymakers developing future treatment guidelines. Ultimately, the study strengthens the knowledge base required to enhance management outcomes and paves the way for further research in improving care for HCC patients globally Experience of delivering More than 200+ Studies Under different therapeutic area Team of experience Professionals 40+ programmers With an average of 10+ years of experience Building a joyful client relationship 10+ satisfied clients Through a commitment to quality and trust. Cost Saving of 30% and more..Commitment to quality and trust. Download Full Report

Exploring the Impact of Study drug on PCOS: Insights from Our Recent Phase III Clinical Study

Exploring the Impact of Study drug on PCOS: Insights from Our Recent Phase III Clinical Study Introduction Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, characterized by irregular menstrual cycles, hyperandrogenism, and polycystic ovaries. Symptoms include weight gain, acne, hirsutism, and infertility, along with metabolic disturbances like insulin resistance and dyslipidemia Download the Case Study Purpose of the Study To evaluate the efficacy and safety of a Study drug in improving clinical and biological parameters in women with PCOS. The study aimed to determine if the Study drug could alleviate symptoms and enhance the overall quality of life by improving gut health and hormonal balance. What we did? Primary Outcome Measure Change in PCOSQ Score: The study measured the change in the Polycystic Ovary Syndrome Questionnaire (PCOSQ) score from baseline to Day 90 to assess the effectiveness of the Study drug in improving the quality of life for women with PCOS. Secondary Outcome Measures Change in PCOSQ score at intermediate time points. Change in scores assessing physical symptoms like hair growth and acne. Change in blood sugar levels and HbA1c. Change in hormone levels, including FSH, LH, estradiol, and testosterone. Change in lipid profile parameters, such as triglycerides, total cholesterol, LDL, and HDL. Safety Endpoints Number of participants who experienced adverse events and those who discontinued the study drug Conclusion The primary outcome measure showed a significant improvement in the PCOSQ score from baseline to Day 90, indicating the effectiveness of the Study drug in enhancing the quality of life for women with PCOS. Secondary outcome measures demonstrated improvements in various clinical and biological parameters, including hormonal balance, insulin sensitivity, and lipid profiles. Safety endpoints were monitored, with a record of participants who experienced adverse events and those who discontinued the study drug. Contact Us Potential Benefits of Probiotics in Managing PCOS Improved Insulin Sensitivity: Probiotics may help enhance insulin sensitivity, a key factor in managing PCOS. Reduced Inflammation: Probiotics can reduce systemic inflammation, which is often elevated in women with PCOS. Hormonal Balance: By supporting gut health, probiotics might help balance hormones, including reducing excess androgen levels. Weight Management: Certain probiotic strains may aid in weight loss and maintenance, beneficial for many women with PCOS. Mood Regulation: Probiotics may improve mood and reduce anxiety, often associated with PCOS Experience of delivering More than 200+ Studies Under different therapeutic area Team of experience Professionals 40+ programmers With an average of 10+ years of experience Building a joyful client relationship 10+ satisfied clients Through a commitment to quality and trust.

Identifying and Rectifying the Human Error in Randomization Plan

Identifying and Rectifying Human Error in Randomization Plan Introduction In clinical trials, accurate application of randomization is crucial for obtaining reliable results in the analysis of study data. However, human errors can significantly impact outcomes, leading to incorrect conclusions. This case study explores a scenario where human error in randomization led to discrepancies between the mean and standard deviation of glucose levels reported by KITE-Ai and Client analyses.. Download the Case Study Background The data presented in this case study is from a diabetes study, where subjects were randomized to active treatment and placebo groups, focusing on glucose levels. Two tables were created, each containing two columns: SUBJID (subject ID) and Glucose Level. Analyses were conducted simultaneously by KITE-Ai and the Client. However, the mean and standard deviation of glucose levels reported by each team did not match, indicating a potential issue. What we did? Data Analysis The discrepancy was traced back to errors in randomization applied by the Client. Specifically: SUBJID 23 and SUBJID 27 were incorrectly included in Active Treatment arm. SUBJID 28 and SUBJID 31, who were supposed to be part of Active Treatment arm, were excluded. This misallocation of subjects caused incorrect glucose level data to be used in the Client’s analysis, thereby affecting the final computed mean and standard deviation values. *Dummy data used, and image is for representation purpose only. The actual data and visualization remain confidential as a part of the CDA and DECP. Impact of Human Error The incorrect randomization had significant consequences: The mean glucose level reported by KITE-AI-Ai was 120.12, whereas the Client reported 122.75. The standard deviation glucose level reported by KITE-Ai was 34.49071, while the Client reported 35.64846. The inclusion of incorrect subjects (SUBJID 23 and SUBJID 27) in the Client’s analysis introduced erroneous data, resulting in a higher mean value. These discrepancies could lead to incorrect conclusions about the efficacy or safety of the treatment under study. Conclusion This case study highlights the critical importance of accurate randomization in clinical trials. Human errors, such as incorrect subject inclusion, can result in significant discrepancies in data analysis, potentially jeopardizing the validity of the trial’s conclusions. It underscores the need for meticulous data management and rigorous verification processes to minimize the risk of such errors and ensure reliable results. Although the case study is from live studies, actual study data is not used here to protect data privacy and dummy is presented here for illustration.  Contact Us Experience of delivering More than 200+ Studies Under different therapeutic area Team of experience Professionals 40+ programmers With an average of 10+ years of experience Building a joyful client relationship 10+ satisfied clients Through a commitment to quality and trust.

Exacerbations in COPD and Role of Tobacco Smoking, Clinical Indicators, and Medication Management​​

Hot News Exacerbations in COPD and Role of Tobacco Smoking, Clinical Indicators, and Medication Management​​ Exacerbations in COPD and Role of Tobacco Smoking, Clinical Indicators, and Medication Management​ Objective of the Study? Assessment of COPD by understanding the burden of severe exacerbations of COPD. Assess the prevalence and impact of tobacco smoking on COPD exacerbations Evaluate the relationship between key clinical indicators (blood eosinophil measurement, COPD Gold Grade, mMRC dyspnea scale, and %FEV1 change) and severe COPD exacerbations, identifying potential predictors for exacerbation risk. Evaluating impact of Respiratory maintenance and reliever treatment medication exposure on exacerbations of COPD. Download the Case Study COPD Data Analysis? Change in Forced Expiratory Volume was analyzed as compared to Baseline for Statistical Significance. COPD data was summarized as per COPD Gold Grade. Summary reports generated to evaluate the relationship between key clinical indicators and severe COPD exacerbations. Patients’ data was summarized as per patients’ Lifestyles to get a summary of Tobacco Smoking. What we did? Patient’s lifestyle in terms of tobacco smoking within the COPD population. It includes the total number of patients (N) within the COPD population, as well as the breakdown of patients based on their smoking status: non-smokers, ex-smokers, and current smokers. The data is further categorized by country, providing insights into smoking prevalence across different regions. -Frequencycounts give the number of patients in each smoking category, while percentages show how smoking status is distributed within the COPD population and across countries. This information can help identify patterns of tobacco use and inform public health interventions aimed at reducing smoking prevalence among COPD patients. Patients’ dyspnea severity based on the Modified Medical Research Council (mMRC) Dyspnea Scale within the COPD population. It presents the total number of patients (N) within the COPD population and the distribution of patients across different dyspnea grades. – The frequency counts provide a detailed breakdown of the number of patients experiencing each dyspnea grade, ranging from Grade 0 (only experiencing breathlessness with strenuous exercise) to Grade 4 (too breathless to leave the house). This comprehensive categorization enables a clear understanding of the distribution of dyspnea severity within the COPD population, delineating the spectrum of symptom severity. Additionally, percentages offer insights into the proportion of patients experiencing each level of dyspnea severity, both overall and within each country. This information can aid in identifying the prevalence of dyspnea and its impact on COPD patients’ quality of life across various regions. Patient’s blood eosinophil measurements within the COPD population. It includes both overall statistics and country-specific data, offering insights into the distribution of blood eosinophil counts (BEC) across different regions. – The frequency counts provide valuable insights into the distribution of blood eosinophil levels within the COPD population, categorizing patients into different categories such as BEC < 100 cells/uL, 100 cells/uL ≤ BEC ≤ 300 cells/uL, and BEC > 300 cells/uL. Additionally, percentages offer further understanding by indicating the proportion of patients within each blood eosinophil level category, both overall and within each country. This information can aid in identifying patterns of eosinophilic inflammation and its potential implications for COPD management across various regions. Patient’s COPD GOLD grade classification based on airflow limitation within the COPD population. Frequency: The frequency counts provide the number of patients falling within each COPD GOLD grade such as, GOLD FEV1% predicted ≥80%, GOLD 2: FEV1 % predicted 50-79% , GOLD 3: FEV1% predicted 30-49% ,GOLD 4: FEV1 % predicted Analysis of the change in %FEV1 (forced expiratory volume in one second as a percentage of predicted) from baseline to post-baseline within the COPD population. Baseline refers to the initial measurement or assessment taken at the beginning of a study or intervention. Here baseline %FEV1 measurement represents the lung function level at the start of the study or intervention. Postbaselinerefers to measurements or assessments taken after a certain period following the baseline assessment. Here, post-baseline measurements are typically taken at specific time points after the initiation of treatment or intervention. P-value: – The p-value is calculated using statistical tests such as the paired t-test or Wilcoxon signed-rank test todetermine the significance of the observed change in %FEV1 from baseline to post-baseline. – A low p-value (<0.05) indicates that the observed change is statistically significant, suggesting that there is a real Contact Us Experience of delivering More than 200+ Studies Under different therapeutic area Team of experience Professionals 40+ programmers With an average of 10+ years of experience Building a joyful client relationship 10+ satisfied clients Through a commitment to quality and trust.